Stay updated on Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The study record for the completed METEOR trial is displayed, including its comparison of cabozantinib with everolimus for metastatic renal cell carcinoma, study methods and outcomes, eligibility criteria, and locations.
    Difference
    100%
    Check dated 2026-11-09T12:35:32.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T11:57:31.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    A site-wide notice was added about NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology. The study page itself remains a 403 error page.
    Difference
    1%
    Check dated 2026-10-26T11:21:20.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2 while the study page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-19T12:18:55.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The revision label in the site footer changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T14:33:53.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The METEOR study record page now displays a 403 Forbidden error, replacing the usual study details with an error screen and removing access to the study content.
    Difference
    15%
    Check dated 2026-09-21T20:39:24.000Z thumbnail image

Stay in the know with updates to Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page.